ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Incyte will acquire Escient Pharmaceuticals, a clinical-stage company specializing in neurosensory-inflammatory disorders, for $750 million. Incyte will get Escient’s lead drugs, the small molecules EP262 and EP547. EP262 is being developed to treat chronic urticaria and atopic dermatitis, while EP547 is targeted at cholestatic and uremic pruritus. The drugs could launch as early as 2029, Incyte’s CEO Hervé Hoppenot says in a press release.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X